Diabetes: Normal glucose levels should be the goal

Nature Reviews Endocrinology

Volumn 8, Issue 9, 2012, Pages 510-512

  Phillips, Lawrence S ^a   Olson, Darin E ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; METFORMIN; PLACEBO; SULFONYLUREA;

DISEASE COURSE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HIGH RISK PATIENT; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN SENSITIVITY; LIFESTYLE MODIFICATION; MEDICAL PRACTICE; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; SCREENING;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; PREDIABETIC STATE;

EID: 84865236468     PISSN: 17595029     EISSN: 17595037     Source Type: Journal    
DOI: 10.1038/nrendo.2012.139     Document Type: Review

References (11)

1. Trial Research Group. Ann. Intern. Med. 128, 517-523 (1998).
2. Stratton, I. M. et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321, 405-412 (2000).
3. Phillips, L. S. et al. Glucose challenge test screening for prediabetes and undiagnosed diabetes. Diabetol. 52, 1798-1807 (2009).
4. The ORIGIN Trial Investigators. Basal insulin and cardiovascular and other outcomes in dysglycemia. N. Engl. J. Med. http://dx.doi.org/10.1056/ NEJMoa1203858.
5. Gong, Q. et al. Long-term effects of a randomised trial of a 6-year lifestyle intervention in impaired glucose tolerance on diabetes-related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study. Diabetol. 54, 300-307 (2011).
6. Perreault, L. et al. Effect of regression from prediabetes to normal glucose regulation on long-term reduction in diabetes risk: results from the Diabetes Prevention Program Outcomes Study. Lancet 379, 2243-2251 (2012).
7. Butler, A. E. et al. β-cell deficit and increased β-cell apoptosis in humans with type 2 diabetes. Diabetes 52, 102-110 (2003).
8. Weyer, C., Bogardus, C., Mott, D. M. & Pratley, R. E. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J. Clin. Invest. 104, 787-794 (1999).
9. Knowler, W. C. et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N. Engl. J. Med 346, 393-403 (2002).
10. Colagiuri, S., Cull, C. A., Holman, R. R. & UKPDS Group. Are lower fasting plasma glucose levels at diagnosis of type 2 diabetes associated with improved outcomes?: U.K. Prospective Diabetes Study 61. Diab. Care 25, 1410-1417 (2002).
11. [No authors listed] Effect of intensive therapy on residual β-cell function in patients with type 1 diabetes in the diabetes control and complications trial. A randomized, controlled trial. The Diabetes Control and Complications